Introduction
It has become clear in recent years that angiogenesis is not only important in physiological processes such as embryonic development, wound healing, and organ and tissue regeneration but also plays a pivotal role in tumor progression and metastasis. 1 If a cancer exceeds the size of B1-2 mm, the recruitment of new blood vessels (angiogenesis) is needed to prevent tumor cell apoptosis. Tumor cells promote angiogenesis by the secretion of angiogenic factors, in particular, basic fibroblast growth factor, and vascular endothelial growth factor (VEGF). 2 Recently, evidence emerged that angiogenesis is tightly regulated by a balance of activating and inhibiting factors. 3 Therefore, continuous delivery of antiangiogenic factors by various means, for instance, might counteract tumor-induced angiogenesis.
TSP-2 is a 450-kDa homotrimeric matricellular glycoprotein that acts as a secreted endogenous angiogenesis inhibitor. 4 It has been reported that stromal TSP-2 is upregulated as a host antitumor defense mechanism, and deficiency of TSP-2 in mice results in accelerated and enhanced skin carcinogenesis and angiogenesis. 5 Recently, systemic delivery of TSP-2 by cell-based therapy and stable overexpression of TSP-2 in tumor cell lines were shown to inhibit both tumor growth and tumor vascularization. 6, 7 As angiostatic therapy will require a prolonged maintenance of the therapeutic levels in vivo, the continuous delivery of a recombinant protein will be expensive and cumbersome. Direct in vivo delivery of the corresponding genes with viral vectors constitutes an attractive solution to this problem. In this study, we constructed retroviral and adenoviral vectors that express the N-terminal fragment (amino acids 1-551) from murine TSP-2 (NfTSP2), still having the antiangiogenic potential, and we assessed its in vivo activity in mouse TS/A breast carcinoma and in the human A431 squamous cell carcinoma model. Here, we report that the intratumoral injection of the syngenic cell line expressing NfTSP2 or the recombinant adenovirus expressing NfTSP2 to carcinomas potently inhibited tumor growth by perturbing tumor-associated angiogenesis.
Results
Syngenic cell line expressing NfTSP2 prevents TS/A establishment and reduces tumor growth TSP-2 is a large multifunctional protein consisting of 1172 amino acids and therefore bears various disadvantages when the whole unit is used as a therapeutic agent. 8, 9 To exclude such possibility, we chose to use the N-terminal antiangiogenic fragment of TSP-2 (amino acids 1-551; NfTSP2). To test the therapeutic effects of NfTSP2 in the context of gene therapy, we took the ex vivo approach using an MLV-based retrovirus (Figure 1a ). We first constructed the syngenic fibroblast cell line, TIB80, which constitutively expresses NfTSP2. As described in Material and methods, TIB80 cells were transduced with the MIN5-NfTSP2 retroviral vector and selected with G418 until a drug-resistant population was obtained. The presence and expression of the NfTSP2 gene were confirmed by genomic DNA PCR and real-time quantitative RT-PCR using primers specific for MIN5-NfTSP2 (Figure 1b and c) .
To test the antitumor potential of the TSP2 fragment, TIB80 cells expressing NfTSP2 were injected directly into the established tumor. A total of 1 Â 10 5 of TS/A cells were injected subcutaneously (s.c.) into the flanks of the mice (day 0). After 5 days, mice having a similar size (30-40 mm 3 ) of tumor volume were selected, divided into two groups, and injected with 1 Â 10 6 of TIB80 expressing NfTSP2 or control cells containing the vector expressing only the neo gene. Animals were checked daily, and tumor sizes were measured every 3-4 days. By day 12 after tumor implantation, a statistically significant difference could be observed between the treated and the control groups (Po0.005) (Figure 2a) . The growth rate of the NfTSP2-treated group was significantly slower than that in the controls, resulting in a 70% reduction of tumor size in the treatment group at day 26 (Po0.005). Furthermore, in 22% of mice treated with NfTSP-2-expressing cells, the established tumors had actually disappeared. On the contrary, 100% of mice injected with the control cells developed tumors (Figure 2b) .
To confirm the antitumor effect of NfTSP2 gene therapy, we performed another experiment using a different treatment strategy. Similar to the above experiment, 1 Â 10 5 of TS/A cells were injected intradermally into the flanks of the mice (day 0). On day 11, mice having a similar size (60-70 mm 3 ) of tumor volume were selected, divided into two groups, and injected with 5 Â 10 6 of TIB80 expressing NfTSP2 or control cells. To maximize the therapeutic effect, treatment was performed again on days 18 and 25. Consistent with the results from the above experiment, the growth rate of the NfTSP2-treated group was significantly slower than that in the controls, resulting in a 65% reduction of tumor size in the treatment group at day 39 (Po0.005) (Figure 3a) . . Mouse NfTSP2 and neo are expressed as a bicistronic message from the LTR. The backbone of the vector has been described previously. 20 Positions of amplification primers that were used in PCR are shown. Stable transduction of TIB80 cells by MIN5-NfTSP2 was confirmed by genomic DNA PCR (b), and real-time quantitative RT-PCR (c), using primers specific for MIN5-NfTSP2. As an internal control, mice b-actin sequences were amplified. LTR, long terminal repeat; SD, splicing donor; SA, splicing acceptor; IRES, internal ribosomal entry site. 
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In addition, the established tumors had disappeared in 38% of the NfTSP2-treated mice ( Figure 3b ). These results clearly showed that ex vivo gene therapy using NfTSP2 could suppress the tumor growth and establishment.
Adenoviral vector expressing NfTSP2 reduces the growth of squamous cell carcinoma and tumor-associated angiogenesis
To confirm the antitumor effects of NfTSP2, we generated the recombinant adenoviral vector expressing NfTSP2 (Ad-NfTSP2) using the adenovirus genomic DNA-terminal protein complex (DNA-TPC) cotransfection method as described in Materials and methods. 10 The expression of NfTSP2 by Ad-NfTSP2 was examined by Western blot analysis. A431 of the human squamous carcinoma cell line was transduced with an MOI of 100 PFU of Ad-NfTSP2 or Ad-LacZ, respectively, and serum-free supernatant was concentrated and used for Western blot analysis. As shown in Figure 4a , the 70-kDa band, corresponding to the size of NfTSP2, was detected in the supernatant from A431 cells transduced with AdNfTSP2, but not in that with the control virus. These results showed that NfTSP2 is successfully secreted into the supernatant of Ad-NfTSP2-transduced cells.
To evaluate the in vitro antiangiogenic activity of NfTSP2, the effects of NfTSP2 on the VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs) were examined. In the absence of VEGF, there was no significant difference in the proliferation rate between the Ad-LacZ-and Ad-NfTSP2-transduced HUVECs. As shown in Figure 4b , the proliferation rate of cells transduced with Ad-LacZ was considerably increased (21.578.6%) in the response to VEGF stimulation, whereas that of Ad-NfTSP2-treated cells was not altered by the addition of VEGF. These results indicated that NfTSP2 could modulate angiogenesis by inhibiting the VEGF-stimulated proliferation of the endothelial cells.
Next, we tested whether the intratumoral injection of Ad-NfTSP2 could reduce the tumor growth and tumor-associated angiogenesis. A431 cells (2 Â 10 6 ) were ), recombinant adenovirus was injected intratumorally. As a control, the same titer of Ad-LacZ was injected into another group of mice. A significant tumor reduction in the treatment group was already seen at day 19 after tumor implantation (Po0.05) (Figure 5a ). At day 34, the tumor volume for the NfTSP2-treated group was decreased to 50% of the control group. Furthermore, the established tumors were eradicated in 14% of NfTSP2-treated mice, while tumors were developed in all of the control mice (Figure 5b) .
Histological analysis by standard hematoxylin/eosin staining and immunohistochemisty with CD31 Ab and CD105 Ab of A431 tumor showed decreased vascularization in the Ad-NfTSP2-treated animals ( Figure 6 ). To achieve a more detailed quantification of the effects of NfTSP2 on tumor angiogenesis, the average vessel size and percentage of tissue area covered by vessels (total vessel area) were determined by computer-assisted image analysis of representative digital images. Whereas 
the control tumors demonstrated about 2500 mm 2 of the average vessel size, the average size was reduced by more than 50% in NfTSP2-treated tumors (Figure 7a and  b) . The result from size distribution analysis showed that NfTSP2 gene transfer resulted in the significant decrease of blood vessels larger than 3000 mm 2 (Figure 7c and d) . Furthermore, total vessel area was reduced by more than 50% in treated tumors as compared with the control tumors (Figure 7e and f) . Similar to the recent findings, 7 there was no significant difference in the average vessel density between the control and the NfTSP2-treated group (data not shown). These results clearly showed that the intratumoral injection of Ad-NfTSP2 inhibited the tumor growth by perturbing tumor-induced angiogenesis.
Discussion
In this study, we have constructed a recombinant retrovirus and adenovirus expressing the N-terminal antiangiogenic fragment of TSP-2 (NfTSP2). We also generated a syngenic fibroblast cell line expressing NfTSP2 using the above retroviral vector. The treatment of tumor-bearing mice with the NfTSP2-expressing cell line or adenovirus led to a tumor volume reduction of up to 50-70% as compared with the controls, and furthermore eradicated the established tumors in 14-38% of treated mice. Histological data demonstrated decreased tumor vascularization, determined as decreased average vessel size and total vessel area, in the NfTSP2-treated mice.
Similar to another member of the TSP gene family, TSP1, TSP2 has the characteristic conserved amino-acid sequences known as type I, type II, and type III repeats.
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It has been reported that the antiangiogenic activity of TSP1 was localized to the three, 60 residue segments of type I repeats with homology to malarial proteins, properdin, and complement proteins C6-C9. 11, 12 The Nterminal fragment of TSP1 (bp 180-1829), which contains the three type I repeats of TSP1 as well as heparinbinding domain, has been shown to be inhibitory to human dermal microvascular endothelial cell angiogenesis. 13 Based on these reports concerning TSP1, we generated the N-terminal fragment of TSP2, NfTSP2, which contains the three type I repeats of TSP2 and examined the antitumor effect of NfTSP2. In agreement with the result from the TSP1 study, NfTSP2 was also found to possess antitumor activity with perturbing tumor-associated angiogenesis in vivo in this study. These results indicate that the antiangiogenic activity of TSP2 may also be localized to three type I repeats as in the case of TSP1.
A growing number of antiangiogenesis strategies have been investigated for the treatment of cancer and other angiogenesis-dependent diseases.
14 One of the most promising strategies is to administer locally one or more antiangiogenic proteins frequently enough to achieve a sufficient long-term steady-state level of the protein(s) to achieve the maximum beneficial effect. However, the utility of this strategy is limited because of many technical difficulties, including obtaining both the required quantity and quality of the protein(s) necessary for optimal therapeutic benefit and the cumbersome daily administration of the proteins. 15, 16 To explore the possibility that tumor growth can be regulated by gene therapy using NfTSP2 as the therapeutic gene, we chose to use both ex vivo retrovirusmediated cell therapy and in vivo adenovirus-mediated gene therapy. To reach the therapeutic goal, we used 1-5 Â 10 6 of NfTSP2-expressing cell line or 1 Â 10 9 PFU of NfTSP2-encoding adenovirus. The inhibitory effect on tumor growth of both strategies was comparable. The treatment of tumor-bearing mice with NfTSP2-expressing cell lines or adenovirus led to a tumor volume reduction up to 70 or 50%, respectively, as compared with the controls. Histological data demonstrated decreased tumor vascularization in the Ad-NfTSP2-treated animals. We obtained similar results in the experiment where the NfTSP2 gene was transferred by syngenic fibroblasts (data not shown). These results suggested that NfTSP2 gene transfer could inhibit the growth of tumors by perturbing tumor-associated angiogenesis. Similarly, tumor treatment with other antiangiogenic gene transfer such as angiostatin, endostatin, and platelet factor-4 also led to reduced tumor size with inhibiting tumorassociated vascularization. [17] [18] [19] Together with other reports, our data suggested that the delivery of the antiangiogenic genes could constitute an attractive solution to problems that resulted from the usage of recombinant proteins. [17] [18] [19] The present data provide the first demonstration that viral vector-based delivery of the cDNA for NfTSP2 can be used to modulate the tumor growth in the in vivo mouse tumor model. There are many kinds of vector systems that have diverse advantages and limitations to achieve efficient gene transfer. It remains to be elucidated as to which vector system is most suitable for the treatment of tumors using NfTSP2. The present data will encourage further development of NfTSP2-based gene therapy for the treatment of tumors.
Materials and methods
Murine N-terminal angiogenic fragment of TSP-2 cDNA cloning and retrovirus construction Total cellular RNA was extracted from mouse fibroblast line, NIH3T3. First-strand cDNA was amplified by reverse transcription-PCR with oligo(dT) primers (SuperScript II; Life Technologies, Grand Island, NY, USA). The cDNA that encodes for N-terminal antiangiogenic fragment of mouse TSP-2 (NfTSP2) was amplified by PCR (sense primer with SalI-EcoRI-HpaI linker, 5 0 -GTC GAC GAA TTC GTT AAC CTC CTA AGT GTC ACA GGT GGA GAC AAG ATG CTC-3 0 ; antisense primer with an SalI-HpaI linker, 5 0 -GTC GAC GTT AAC CGG GTT GGA TAA GCA TCA ATC AAT AGG-3 0 ) for subcloning into pGEMT-easy (Promega). After sequence confirmation, the murine cDNA encoding the NfTSP2 were cloned into the retroviral vector MIN5, which was derived from the MIN-EI vector, 20 resulting in pMIN5-NfTSP2.
Construction of Ad-NfTSP2
Recombinant adenovirus encoding NfTSP2 were constructed using the adenovirus genomic DNA-TPC cotransfection method according to the manufacturer's instruction as described previously 10 (TaKaRa Bio, Japan). Briefly, the cDNA encoding NfTSP2 gene was Modified TSP2 gene transfer inhibits tumor W Hahn et al cloned into pAxCAwt cosmid, resulting in pAxCANfTSP2. Ad5-NfTSP2 was generated by cotransfection of 293 cells with the pAxCA-NfTSP2 cosmid together with the Ad5 DNA-TPC. Titer of infective adenovirus particles was evaluated by the standard plaque-forming assay with 293 cells.
Cell lines
The TS/A cell line is an aggressive and poorly immunogenic clone derived from murine breast adenocarcinoma. 21 This cell was maintained in RPMI1640 supplemented with 10% fetal bovine serum (FBS). The syngenic fibroblast line TIB80 from BALB/c (ATCC, TIB80) and the human squamous cell carcinoma cell line A431 (ATCC, CRL1555) was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS. NIH3T3 (ATCC, CRL1658) was grown in DMEM supplemented with 10% calf serum. The 293T cell is a subline of the Ad-5-transformed human embryonic kidney cell 293 (ATCC CRL1573) that contains the SV40 T antigen. 22 293T cells were grown in DMEM supplemented with 10% FBS. Each medium used in this study was supplemented with 120 mg/ml of penicillin G (1690 U/mg; Sigma catalog number P-3032, St Louis, MO, USA) and 200 mg/ml of streptomycin sulfate (750 U/mg; Sigma catalog number S-9137).
Generation of stable cell lines expressing N-terminal antiangiogenic fragment of TSP-2 MIN5-NfTSP2 plasmid was transfected into 293T cells with pVM-gp and pVM-VSVG expressing the murine leukemia virus gag-pol and vesicular stomatitis virus (VSV)-G protein, respectively, as described previously. 23 The resulting viral supernatants were used to transduce TIB80 cells seeded the previous day at 2 Â 10 5 on a 60-mm dish. Cells were transferred to 100-mm dishes 24 h after transduction and selected in the presence of G418 (1 mg/ml; Gibco BRL, Gaithersburg, MD, USA) until a viable population formed. As a control, cell lines containing the parental retroviral vector alone (MIN5) were also constructed. Stable transduction of TIB80 cells by MIN5-NfTSP2 were confirmed by genomic DNA PCR for the presence of DNA and real-time quantitative RT-PCR for the production of RNA using primers specific for MIN5-NfTSP2 as described previously. 
Real-time quantitative PCR
For accurate quantitative analysis, real-time quantitative PCR was employed using the ABI Prism 7700 sequence detector system (PE Biosystems, Foster City, USA) as described previously. 22, 24 The amount of fluorescence measured in a sample is proportional to the amount of specific PCR product generated. C T values corresponding to the cycle number at which the fluorescent emission monitored in real time reaches a threshold of 10 times the standard deviations of the mean baseline emission from cycles 1 to 15 were measured.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting
The A431 cells were transduced with Ad-NfTSP2 and Ad-LacZ at an MOI of 100, respectively. At 2 days after transduction, the culture supernatants were obtained from the transduced cells and NfTSP2 were concentrated as described. 6, 25 Samples were mixed with a one-third volume of SDS sample buffer, heated at 981C for 5 min, and subjected to SDS-PAGE on a 10% polyacrylamide gel. After electrophoresis, the samples were transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was incubated at room temperature for 2 h with rabbit anti-murine TSP2 Ab (see below), then incubated with horseradish peroxidase-conjugated anti-rabbit IgG (Pierce, Rockford, IL, USA), washed, and processed for autoradiography using chemiluminescence techniques (ECL kit: Amersham, IL, USA), according to the manufacturer's instructions.
Development of anti-murine TSP2 antibody
The 15 amino-acid peptide VKDTSFDLFDLFSISNIN derived from the N-terminal sequence of the murine TSP2 coding region (amino acids 22-36) was used to generate anti-murine TSP2 Ab as previously described with slight modification. 6 
Cell proliferation assay
Cell proliferation assays were performed as described previously. 26 HUVECs (AngioLab, Daejeon, Korea) were cultured in Medium 199 (Gibco BRL), and then supplemented with 10% FBS (Gibco BRL), 50 mg/ml of endothelial cell growth (Sigma), and 50 mg/ml of heparin (Sigma). HUVECs at passages 3-5 were seeded onto sixwell plates, infected at an MOI of 50 with adenoviral vectors expressing LacZ or NfTSP2, and cultured in medium containing 5% FBS for 24 h. The cells were then trypsinized, replated at a density of 1 Â 10 4 cells/well onto 96-well plates, and incubated in the presence or absence of 50 ng/ml of recombinant VEGF (AngioLab). At 4 days after the addition of VEGF, cell proliferation was determined using Cell Titer96 Aqueous Assay (Promega, Madison, WI, USA), according to the manufacturer's recommendations.
In vivo evaluation of tumor growth
To test whether NfTSP2 gene transfer can inhibit tumor growth, cells (1 Â 10 5 of TS/A or 2 Â 10 6 of A431 cells) were injected s.c. into the flanks of BALB/c or nude mice. After the indicated days, mice having a similar size of tumor volume were selected and divided, and received an intratumoral injection of TIB80 cells transduced with MIN5-NfTSP2 or Ad-NfTSP2. As a control, the same amount of control TIB80 cells or Ad-LacZ was injected. Tumors were measured with calipers in two dimensions every 3-5 days, and the volume was calculated as length Â width 2 Â 0.52 as described previously.
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Histologic processing and analysis of tumor tissues
Tumor tissues were dissected, fixed, dehydrated, and embedded in paraffin. Standard frontal sections of 7 mm were prepared, stained with hematoxylin and eosin.
Immunohistochemical staining was also performed on 7 mm frozen or paraffin sections by using an anti-murine Modified TSP2 gene transfer inhibits tumor W Hahn et al CD31 Ab (Pharmigen, CA, USA) or anti-murine CD105 Ab (Pharmigen), followed by a peroxidase-conjugated rabbit anti-rat IgG Ab (Pierce). Sections stained with appropriate antibodies were analyzed using an Olympus BX60 microscope. Images were captured with a Spot digital camera, and morphometric analyses were performed using Image-Pro Plus software (Media Cybernetics, MD, USA). Three different fields in each section were examined at Â 40 magnification, and the number of vessels/mm 2 , average vessel size, and relative area covered by blood vessels were determined as described previously. 6 
Statistical analysis
Differences between experimental groups were tested using the Mann-Whitney rank-sum test, unless otherwise stated. P-values less than 0.05 were considered significant.
